Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ANI PharmaceuticalsFRA:BSFA -2.94%78 Interest Coverage is 10.27 as of Mar. 2026, which is 335% above its 10-year median of 2.36. GuruFocus rates FRA:BSFA with a GF Score™ of 78/100 and a GF Value™ of €83.99 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 684 Drug Manufacturers companies, ANI Pharmaceuticals ranks worse than 67.69% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. ANI Pharmaceuticals's
Operating Income
for the
three
months ended in Mar. 2026 was €33.5 Mil. ANI Pharmaceuticals's Interest Expense for the
three
months ended in Mar. 2026 was €-3.3 Mil.
ANI Pharmaceuticals's interest coverage for the quarter that ended in Mar. 2026 was 10.27.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for ANI Pharmaceuticals's Interest Coverage or its related term are showing as below:
FRA:BSFA'
s Interest Coverage Range Over the Past 10 Years
Min: 0.13 Med: 2.36 Max: 5.77
Current: 5.77
FRA:BSFA's Interest Coverage is ranked worse than 67.69% of 684
companies
in the Drug Manufacturers industry
Industry Median: 12.765
vs FRA:BSFA: 5.77
ANI Pharmaceuticals (FRA:BSFA) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
ANI Pharmaceuticals Interest Coverage Related Terms
ANI Pharmaceuticals Interest Coverage Historical Data
* Premium members only.
The historical data trend for ANI Pharmaceuticals's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:BSFA vs TRLV, AMLX, XERS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANI Pharmaceuticals Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals (FRA:BSFA) has a Interest Coverage of 10.27 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on ANI Pharmaceuticals and its competitors. This is 335% above median its historical median of 2.36. Over the past decade, ANI Pharmaceuticals' Interest Coverage has ranged from 0.13 to 5.77. According to the industry distribution chart, ANI Pharmaceuticals ranks #463 out of 684 companies in the Drug Manufacturers industry, placing it in the top 67.7%.
Is ANI Pharmaceuticals' Interest Coverage too high?
ANI Pharmaceuticals' current Interest Coverage of 10.27 is 335% above median its 10-year median of 2.36. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 5.77. The Drug Manufacturers industry median Interest Coverage is 12.77. ANI Pharmaceuticals' value of 10.27 is 19.5% below this industry median. Based on the distribution chart, ANI Pharmaceuticals ranks #463 out of 684 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, ANI Pharmaceuticals has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' Interest Coverage compare to TRLV and AMLX?
According to the Drug Manufacturers industry distribution chart, ANI Pharmaceuticals ranks #463 out of 684 companies for Interest Coverage. This places ANI Pharmaceuticals in the lower half of its industry. The industry median Interest Coverage is 12.77. ANI Pharmaceuticals' value of 10.27 is 19.5% below this benchmark. Historically, ANI Pharmaceuticals' own Interest Coverage has ranged from 0.13 to 5.77 over the past decade. While the company's 10-year median is 2.36 vs. the industry median of 12.77, ANI Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANI Pharmaceuticals's current Interest Coverage of 10.27 is 19.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on ANI Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANI Pharmaceuticals's current Interest Coverage is 10.27, which is 335% above median its own 10-year median of 2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (FRA:BSFA) is currently considered Modestly Undervalued. The stock's GF Value™ is €83.99, compared to a current price of €66.00 — trading 21.4% below its estimated fair value. The current Interest Coverage is 10.27, which is 335% above median its 10-year median of 2.36 and 19.5% below the Drug Manufacturers industry median of 12.77. ANI Pharmaceuticals' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For ANI Pharmaceuticals (FRA:BSFA), the current Interest Coverage is 10.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANI Pharmaceuticals (FRA:BSFA) Overvalued in 2026?
Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued.
The current stock price of €66.00 is trading 21.4% below its estimated GF Value™ of €83.99.
GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for FRA:BSFA:
Interest Coverage: 10.27 (335% above median its 10-year median of 2.36)
GF Value™: €83.99 vs. price of €66.00 (21.4% below fair value)
Industry Position: 19.5% below the Drug Manufacturers median (#463 of 684)
No single metric tells the full story. See the FRA:BSFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
78GF Score
Get the complete analysis for FRA:BSFA
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BSFA has been successfully added to your 
